Table 5.

Clinical outcomes of patients with PI3K/AKT pathway genetic alterations harboring simultaneous RAS/RAF/MEK pathway genetic alterations (N = 9)

Patients no.Tumor typePI3K pathway genetic alterationMAPK pathway genetic alterationTarget of study drugResponse (RECIST %)TTP, wk
1ColonPTEN deletionKRAS G12D mutationMEK1/2PD (+35)4.0
2ColonPTEN deletionKRAS G13D mutationP38MAPKSD (+10)5.2
3ColonPTEN deletionKRAS G12D mutationmTORC1PD (+28)9.7
4ColonPTEN deletionKRAS G13D mutationmTORC1PD (ascites)10.4
5ColonPTEN deletionKRAS G12D mutationmTORC1 + MEK1/2SD (−2)12.7
6ColonAKT2 amplificationKRAS G12D mutationmTORC1 + MEK1/2SD (−3)16.0
7MelanomaPTEN deletionBRAF V600E mutationmTORC1 + MEK1/2SD (−2)17.2
8MelanomaPTEN deletionBRAF V600E mutationmTORC1 + MEK1/2PR (−64)45.8
9ColonAKT2 amplificationMAP3K10 amplificationAKT + MEK1/2SD (−2)15.8

Abbreviations: PR, partial response; PD, progressive disease; SD, stable disease.